TAIPEI, May 6, 2024 – REGiMMUNE Limited, a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies for immune disorders and cancer, is pleased to announce the appointment of Dr. Steve Yang as its Chief Operating Officer (COO), effective on May 6th 2024. In this role, Dr. Yang will lead the company’s operational strategies, driving product development and innovation to foster REGiMMUNE’s growth across all aspect.

With over 20 years of extensive experience in the biotech industry, Dr. Yang brings a wealth of knowledge and leadership to REGiMMUNE. Prior to joining REGiMMUNE, he has founded a CRO to provide comprehensive clinical research services to several big pharmas. He has also joined Industrial Technology Research Institute (ITRI) to conduct project management and business development for various biomedical products. His proven track record of success in research and business development, aligns seamlessly with REGiMMUNE’s goals. REGiMMUNE also would like to leverage Dr. Yang’s business exposure as a senior executive in the TSE-listed company to accelerate the process of entering the capital market in Taiwan.

“We are thrilled to welcome Steve Yang to the REGiMMUNE team,” said Kenzo Kosuda, the chairman and the CEO of REGiMMUNE. “With his exceptional leadership skill and industry expertise, he will play a pivotal role in driving our company forward as we continue to expand global market through Taiwan-Japan collaboration. We are confident that he will make significant contributions to our growth and success.”

Dr. Yang expressed enthusiasm about his new role in REGiMMUNE, stating, “I’m extremely grateful to join this great company with distinctive pipeline and ambitious management team! REGiMMUNE signifies the deepening collaborative relationship between Japan and Taiwan. I strongly believe that this formula of success will bring fruitful progress to the medical profession and patients, and deliver value to all of our stakeholders in the shortest time!”

Steve Yang holds a PhD degree in Healthcare Organization and Research from Medical College of Virginia. He will be based at REGiMMUNE’s headquarters in Taipei, Taiwan, and will report directly to the CEO.



About REGiMMUNE Limited

REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies by harnessing the power of regulatory T cells (Tregs). REGiMMUNE is creating a pipeline of novel product candidates that either enhance Treg activities for immune diseases or suppress Treg activities for cancer.

Corporate Contact

Miranda Yu
Investor Relations Manager
REGiMMUNE Corporation Ltd.
+886 2 2555 3377 #511




202456日,台北 瑞格國際生技,一家致力於開發免疫性疾病和癌症新型療法的臨床階段生技公司,很高興宣佈任命楊思聖博士擔任集團營運長 (COO) ,任期自2024年5月6日起生效。在這一職位上,楊博士將領導公司的營運策略,推動產品開發和創新,以促進瑞格在各方面的成長。

楊博士在生醫產業擁有超過20年的豐富經驗。在加入瑞格之前,他創辦了一家臨床研究服務公司,為多家大型藥廠提供臨床研究服務;他還加入了工業技術研究院 (ITRI),參與多種生醫產品的研發管理和商業開發。他在研究和業務發展方面的成功經驗與瑞格的目標吻合,瑞格也希望透過楊博士曾經擔任上市公司高階管理員的商業背景加快進入台灣資本市場的過程。









余明穎 (Miranda Yu)
+886 2 2555 3377 #511